Holen Sie sich die Stockscreener-App
21.19
3.37%
-0.74
Vorhandelsmarkt:
21.15
-0.04
-0.19%
Schlusskurs vom Vortag:
$21.93
Offen:
$21.79
24-Stunden-Volumen:
798.11K
Relative Volume:
0.62
Marktkapitalisierung:
$1.51B
Einnahmen:
Nettoeinkommen (Verlust:
$-170.73M
KGV:
-7.8712
EPS:
-2.6921
Netto-Cashflow:
$-159.70M
1W Leistung:
-3.73%
1M Leistung:
-41.02%
6M Leistung:
-53.42%
1J Leistung:
-19.70%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$21.13
$23.83
52-Wochen-Spanne:
$20.73
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
21.19 | 1.51B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Structure (GPCR) Stock Analysis: Falls -5.00%, Watching $20.03 2026-10-18Volatility Surface - https://www.dars.gov.et/
GPCR Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesEarnings Quality Score - www.dars.gov.et
GPCR Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesEPS Miss Report - dars.gov.et
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
Structure Therapeutics (GPCR) Trades at $25.54, Sitting at the Midpoint of Its Recent RangeEntry Point Alerts - https://www.siam.in/
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Structure Therapeutics (GPCR) Slides 5.23% to $33.23, Pulling Back Toward Key Support at $31.57FRAMA Signal - https://www.dars.gov.et/
Structure Therapeutics (GPCR) Slides 5.23% to $33.23, Pulling Back Toward Key Support at $31.57Bull Flag - https://www.siam.in/
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? - Zacks Investment Research
Structure Therapeutics (NasdaqGM:GPCR) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com Canada
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com India
Structure Therapeutics (GPCR) CMO sells shares under preset plan - Stock Titan
Structure Therapeutics Inc. (GPCR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com UK
Structure Therapeutics Inc.American Depositary Shares (Nasdaq:GPCR) Price Chart - The Chronicle-Journal
Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily
Structure Therapeutics at Cantor conference: oral obesity push advances By Investing.com - Investing.com Canada
Structure Therapeutics at Cantor conference: oral obesity push advances - Investing.com
Structure Therapeutics Advances ACCG-2671 with 3.3% Weight Loss; Aleniglipron Hits 16.2% Reduction (NASDAQ: GPCR) - Kalkine Media
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data - investing.com
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com UK
Structure Therapeutics (GPCR) Shares Slide After Obesity Drug Tr - GuruFocus
Jefferies raises Structure Therapeutics stock target on amylin data By Investing.com - Investing.com Canada
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Zacks Investment Research
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results - TipRanks
Oral obesity drug shows double-digit weight loss as Structure Therapeutics (NASDAQ: GPCR) advances Phase 3 trials - Stock Titan
A weight-loss pill cut body weight 16.2% in 72 weeks - Stock Titan
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
Morgan Stanley’s conference is one of three Structure Therapeutics plans to join in September - Stock Titan
Structure Therapeutics (GPCR) CSO sells 5,939 ADSs under preset plan - Stock Titan
Barinthus Biotherapeutics advances court-approved merger, Nasdaq exit - The Globe and Mail
(GPCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - Eastern Progress
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Structure (GPCR) Watch: Finishes 6.67% Down at $50.52 in the Current Update; Range Check: Support at $47.99 and Resistance at $53.05 Frame the Range at the CloseMomentum ETF - dars.gov.et
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - Eastern Progress
Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure (GPCR) Watch: Finishes 6.67% Down at $50.52 in the Current Update; Range Check: Support at $47.99 and Resistance at $53.05 Frame the Range at the CloseComposite Profile - www.dars.gov.et
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionRevenue Warning Signal - dars.gov.et
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionRevenue Guidance Update - careplusvn.com
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionNegative Surprise Momentum - dars.gov.et
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Structure Therapeutics Inc Adr-Aktie (GPCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Sep 01 '26 |
Option Exercise |
0.34 |
17,817 |
6,058 |
246,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Aug 18 '26 |
Option Exercise |
0.34 |
11,817 |
4,018 |
240,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Aug 04 '26 |
Option Exercise |
0.34 |
11,817 |
4,018 |
240,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jul 14 '26 |
Option Exercise |
0.34 |
23,634 |
8,036 |
252,594 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jun 25 '26 |
Option Exercise |
0.34 |
23,634 |
8,036 |
252,594 |
| XICHEN LIN | Officer |
Jun 25 '26 |
Proposed Sale |
48.16 |
35,512 |
1,710,258 |
0 |
0.58%
1.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):